International Diabetes Federation. IDF Diabetes Atlas. 10ª ed. Bruselas; 2021.

Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial, Diabetes control and complications trial research group. J. Pediatr. 125(2), 177–188 (1994)

Google Scholar 

N.H. White, P.A. Cleary, W. Dahms, D. Goldstein, J. Malone, W.V. Tamborlane, Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J. Pediatr. 139(6), 804–812 (2001).

Article  CAS  PubMed  Google Scholar 

R.R. Holman, S.K. Paul, M.A. Bethel, D.R. Matthews, H.A. Neil, 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med 359(15), 1577–1589 (2008)

Article  CAS  PubMed  Google Scholar 

E. Maddaloni, N. Lessan, A. Al Tikriti, R. Buzzetti, P. Pozzilli, M.T. Barakat, Latent autoimmune diabetes in adults in the United Arab Emirates: clinical features and factors related to insulin-requirement. PLoS ONE 10, e0131837 (2015)

Article  PubMed  PubMed Central  Google Scholar 

Z. Zhou, Y. Xiang, L. Ji, W. Jia, G. Ning, G. Huang, L. Yang, J. Lin, Z. Liu, W.A. Hagopian, R.D. Leslie; LADA China Study Group, Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in China (LADA China study): a nationwide, multicenter, clinic-based cross-sectional study. Diabetes 62(2), 543–550 (2013)

Article  CAS  PubMed  PubMed Central  Google Scholar 

M.I. Hawa, H. Kolb, N. Schloot, H. Beyan, S.A. Paschou, R. Buzzetti, D. Mauricio, A. De Leiva, K. Yderstraede, H. Beck-Neilsen, J. Tuomilehto, C. Sarti, C. Thivolet, D. Hadden, S. Hunter, G. Schernthaner, W.A. Scherbaum, R. Williams, S. Brophy, P. Pozzilli, R.D. Leslie; Action LADA consortium, Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7. Diab. Care 36(4), 908–913 (2013)

Article  Google Scholar 

V. Tyndall, R.H. Stimson, N.N. Zammitt, S.A. Ritchie, J.A. McKnight, A.R. Dover et al. Marked improvement in HbA1c following commencement of flash glucose monitoring in people with type 1 diabetes. Diabetologia 62(8), 1349–1356 (2019)

Article  CAS  PubMed  PubMed Central  Google Scholar 

G. Yadegarfar, S.G. Anderson, Z. Khawaja, G. Cortes, K. Leivesley, A. Metters et al. The FreeStyle Libre flash glucose monitoring system: how it has improved glycaemic control for people with type 1 diabetes in Eastern Cheshire, UK. Cardiovasc Endocrinol. Metab. 9(4), 171–176 (2020)

Article  CAS  PubMed  PubMed Central  Google Scholar 

M. Evans, Z. Welsh, A. Seibold, Reductions in HbA1c with Flash Glucose Monitoring are sustained for up to 24 months: a meta-analysis of 75 real-world observational studies. Diab. Ther. 13(6), 1175–1185 (2022)

Article  CAS  Google Scholar 

K. Eeg-Olofsson, A.M. Svensson, S. Franzén, H. Ahmed Ismail, M. Törnblom, F. Levrat-Guillen, Real-world study of flash glucose monitoring among adults with type 2 diabetes within the Swedish National Diabetes Register. Diab Vasc. Dis. Res 20(1), 14791641211067418 (2023)

Article  PubMed  PubMed Central  Google Scholar 

F. Gomez-Peralta, T. Dunn, K. Landuyt, Y. Xu, J.F. Merino-Torres, Flash glucose monitoring reduces glycemic variability and hypoglycemia: real-world data from Spain. BMJ Open Diab. Res Care 8(1), e001052 (2020)

Article  PubMed  PubMed Central  Google Scholar 

R. Jiménez-Sahagún, E. Gómez Hoyos, G. Díaz Soto, M.O. Nieto de la Marca, M. Sánchez Ibáñez, S. Del Amo Simón et al. Impact of flash glucose monitoring on quality of life and glycaemic control parameters in adults with type 1 diabetes mellitus. Endocrinol. Diab. Nutr. 69(5), 345–353 (2022).

Google Scholar 

M.P. Bahíllo-Curieses, G. Díaz-Soto, A.M. Vidueira-Martínez, I. Torres-Ballester, E. Gómez-Hoyos, D. de Luis-Román, Assessment of metabolic control and use of flash glucose monitoring systems in a cohort of pediatric, adolescents, and adults patients with Type 1 diabetes. Endocrine 73(1), 47–51 (2021)

Article  PubMed  Google Scholar 

E. Fernández, A. Cortazar, V. Bellido, Impact of COVID-19 lockdown on glycemic control in patients with type 1 diabetes. Diab. Res Clin. Pr. 166, 108348 (2020)

Article  Google Scholar 

C. Eberle, S. Stichling, Impact of COVID-19 lockdown on glycemic control in patients with type 1 and type 2 diabetes mellitus: a systematic review. Diabetol. Metab. Syndr. 13(1), 95 (2021)

Article  CAS  PubMed  PubMed Central  Google Scholar 

J. Moreno-Fernandez, J. Sastre, S. Herranz, P. Pinés, F.J. Gomez, I. Quiroga, A.J. Moya, C. Gonzalvo, R. Miralles, D. Calderon-Vicente, M. Palma, J. Gargallo, J.R. Muñoz-Rodriguez, Effect of the historic Spanish heatwave over glycemic control in adult patients with type 1 diabetes. Sci. Total Environ. 16, 164045 (2023)

Article  Google Scholar 

D.C. Klonoff, J. Wang, D. Rodbard, M.A. Kohn, C. Li, D. Liepmann et al. A Glycemia Risk Index (GRI) of hypoglycemia and hyperglycemia for continuous glucose monitoring validated by clinician ratings. J. Diab. Sci. Technol. 17(5), 1226–1242 (2023)

Article  Google Scholar 

P. Pérez-López, P. Férnandez-Velasco, P. Bahillo-Curieses, D. de Luis, G. Díaz-Soto, Impact of glucose variability on the assessment of the glycemia risk index (GRI) and classic glycemic metrics. Endocrine 82(3), 560–568 (2023)

Article  PubMed  PubMed Central  Google Scholar 

J.Y. Kim, J.H. Yoo, J.H. Kim, Comparison of glycemia risk index with time in range for assessing glycemic quality. Diab. Technol. Ther. 25(12), 883–892 (2023)

Article  CAS  Google Scholar 

C. Piona, M. Marigliano, C. Roncarà, E. Mozzillo, F. Di Candia, A. Zanfardino et al. Glycemia risk index as a novel metric to evaluate the safety of glycemic control in children and adolescents with type 1 diabetes: an observational, multicenter, real-life cohort study. Diab. Technol. Ther. 25(7), 507–512 (2023)

Article  CAS  Google Scholar 

T. Battelino, T. Danne, R.M. Bergenstal, S.A. Amiel, R. Beck et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diab. Care 42(8), 1593–1603 (2019)

Article  Google Scholar 

R. Buzzetti, T. Tuomi, D. Mauricio, M. Pietropaolo, Z. Zhou, P. Pozzilli, R.D. Leslie, Management of latent autoimmune diabetes in adults: a consensus statement from an international expert panel. Diabetes 69(10), 2037–2047 (2020)

Article  CAS  PubMed  PubMed Central  Google Scholar 

P.Z. Zimmet, The pathogenesis and prevention of diabetes in adults: genes, autoimmunity, and demography. Diab. Care 18, 1050–1064 (1995)

Article  CAS  Google Scholar 

N.A. ElSayed, G. Aleppo, V.R. Aroda, R.R. Bannuru, F.M. Brown, D. Bruemmer et al. On behalf of the American Diabetes Association. Classification and diagnosis of diabetes: standards of care in diabetes-2023. Diab. Care. 46, S19–S40 (2023)

Article  CAS  Google Scholar 

A. Arranz Martín, E. Lecumberri Pascual, M.A. Brito Sanfiel, V. Andía Melero, L. Nattero Chavez, I. Sánchez López et al. Clinical and metabolic profile of patients with latent autoimmune diabetes in adults in specialized care in Madrid. Endocrinol. Diab. Nutr. 64(1), 34–39 (2017).

Google Scholar 

C.D. Andersen, L. Bennet, L. Nyström, U. Lindblad, E. Lindholm, L. Groop, O. Rolandsson, Worse glycaemic control in LADA patients than in those with type 2 diabetes, despite a longer time on insulin therapy. Diabetologia 56(2), 252–258 (2013)

Article  CAS  PubMed  Google Scholar 

R.S. Weinstock, D. Xing, D.M. Maahs, A. Michels, M.R. Rickels, A.L. Peters et al. Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry. J. Clin. Endocrinol. Metab. 98(8), 3411–3419 (2013)

Article  CAS  PubMed  Google Scholar 

C.M. Fuhri Snethlage, T.J. McDonald, R.D. Oram, P. De Groen, E. Rampanelli, A.W.M. Schimmel et al. Residual β-Cell function is associated with longer time in range in individuals with type 1 diabetes. Diabetes Care; dc230776. (2023). https://doi.org/10.2337/dc23-0776. Epub ahead of print

T.D. Riddlesworth, R.W. Beck, R.L. Gal et al. Optimal sampling duration for continuous glucose monitoring to determine long-term glycemic control. Diab. Technol. Ther. 20(4), 314–316 (2018)

Article  CAS  Google Scholar 

H.K. Akturk, P. Herrero, N. Oliver et al. Impact of different types of data loss on optimal continuous glucose monitoring sampling duration. Diab. Technol. Ther. 24(10), 749–753 (2022)

Article  CAS  Google Scholar 

V.N. Shah, C. Sakamoto, L. Pyle, Optimal sampling duration for continuous glucose monitoring for the estimation of glycemia risk index. Diab. Technol. Ther. 25(2), 140–142 (2023)

Article  CAS  Google Scholar 

E. Eviz, G. Yesiltepe Mutlu, K.E. Karakus, E. Can, T. Gokce, S. Muradoglu, S. Hatun, The advanced hybrid closed loop improves glycemia risk index, continuous glucose monitoring index, and time in range in children with type 1 diabetes: real-world data from a single center study. Diab. Technol. Ther. 25(10), 689–696 (2023)

Article  CAS  Google Scholar